<DOC>
	<DOCNO>NCT01309932</DOCNO>
	<brief_summary>The purpose study determine combination therapy Pegylated Interferon Lambda ( BMS-914143 ) plus Ribavirin ( RBV ) single direct antiviral agent ( BMS-790052 BMS-650032 ) 24 week effective safe treatment Chronic Hepatitis C ( CHC ) compare current standard therapy Pegylated Interferon Alpha-2a plus RBV 48 week .</brief_summary>
	<brief_title>Safety Study Pegylated Interferon Lambda Plus Single 2 Direct Antiviral Agents With Ribavirin</brief_title>
	<detailed_description>Study Classification : Pharmacokinetics/ Pharmacodynamics</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Chronic Hepatitis C , Genotype 1 HCV RNA &gt; 100,000 IU/mL screening ; Seronegative Human immunodeficiency virus ( HIV ) Hepatitis B surface antigen ( HBsAg ) ; Liver biopsy within prior 2 year ; subject compensate cirrhosis enroll cap approximately 10 % Any evidence liver disease HCV ; Coinfection HIV ; Diagnosed suspect hepatocellular carcinoma ; Medical history laboratory value abnormality would prohibit use Pegylated Interferon Alpha2a Ribavirin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>